Product Details
| Product Name:
T56-LIMKi |
CAS No.:
924473-59-6 |
| Purity:
98.61% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | T56-LIMKi |
| Description | T56-LIMKi (T5601640) is a selective inhibitor of LIMK2. |
| Cell Research | T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control[1]. |
| In vitro | T56-LIMKi effectively suppresses the proliferation of various cancer cell lines, including ST88-14, U87, Panc-1, and A549 lung cancer cells, exhibiting IC50 values of 18.3, 7.4, 35.2, and 90 μM respectively. It significantly lowers phosphorylated cofilin (p-cofilin) levels, impairing the growth of pancreatic, glioma, and schwannoma cancer cells. This compound inhibits cofilin phosphorylation, crucial for actin disruption, thereby preventing tumor cell movement, proliferation, and the formation of colonies in soft agar without contact. At concentrations ranging from 10-50 μM, T56-LIMKi dose-dependently decreases p-cofilin in NF1?/? MEFs, with a 30 μM IC50, while not affecting total cofilin levels. Furthermore, a 50 μM dosage of T56-LIMKi significantly reduces the presence of stress fibers in cells. |
| In vivo | T56-LIMKi induces inhibition of cofilin phosphorylation and promotes Panc-1 tumor shrinkage in vivo, with mice treated with T56-LIMKi (60 mg/kg) showing a significant decrease in tumor volume compared to controls[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (128.43 mM)
|
| Keywords | T56-LIMKi | T-56-LIMKi | T56LIMKi | inhibit | LIM Kinase (LIMK) | LIMKs | Inhibitor | T-5601640 | T 5601640 | T56 LIMKi |
| Inhibitors Related | BMS-5 | BMS-3 | CRT-0105950 | LX7101 | TH-257 | SM1-71 | LY2812223 | R-10015 | LIMK-IN-22j | LX-7101 hydrochloride |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Fluorochemical Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:16506-27-7
$32.00 / 1mg
-
CAS:66104-23-2
$47.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$10.00/1kg |
|
Nantong Guangyuan Chemicl Co,Ltd
|
2023-11-16 |
|
|
$19.00/1KG |
|
Hong Kong Tiansheng New Material Trading Co., Ltd
|
2022-01-10 |
United States